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Despite improvements in the ability to control fertility, treat infertility, and reduce maternal, fetal, and infant mortal-
ity, neither the preterm birth rate nor the rate of  long-term dis-
abilities associated with extreme preterm birth has declined.1 
Preterm delivery remains a major healthcare problem, affect-
ing 10% of all births and accounting for >85% of all peri-
natal complications and death. Each year, 5000 to 10 000 
newborns have bronchopulmonary dysplasia (BPD), a chronic 
lung disease that follows ventilator and oxygen therapy for 
acute respiratory failure after preterm birth. BPD is charac-
terized by interrupted development of alveolar structures and 
can be complicated by pulmonary hypertension.2 BPD has 
long-term consequences that extend into adulthood, including 
early-onset emphysema, and currently lacks specific thera-
peutic options.3,4 Understanding how alveoli and the underly-
ing capillary network develop and how these mechanisms are 
disrupted in disease states is critical for developing effective 
therapies for lung regeneration.
Editorial see p 2091 
Clinical Perspective on p 2157
Emerging evidence indicates that endothelial-derived 
angiocrine signals induce and sustain regenerative lung alve-
olarization.5 Vascular endothelial growth factor (VEGF) is 
Background—Bronchopulmonary dysplasia and emphysema are life-threatening diseases resulting from impaired alveolar 
development or alveolar destruction. Both conditions lack effective therapies. Angiogenic growth factors promote 
alveolar growth and contribute to alveolar maintenance. Endothelial colony-forming cells (ECFCs) represent a subset 
of circulating and resident endothelial cells capable of self-renewal and de novo vessel formation. We hypothesized that 
resident ECFCs exist in the developing lung, that they are impaired during arrested alveolar growth in experimental 
bronchopulmonary dysplasia, and that exogenous ECFCs restore disrupted alveolar growth.
Methods and Results—Human fetal and neonatal rat lungs contain ECFCs with robust proliferative potential, secondary 
colony formation on replating, and de novo blood vessel formation in vivo when transplanted into immunodeficient mice. 
In contrast, human fetal lung ECFCs exposed to hyperoxia in vitro and neonatal rat ECFCs isolated from hyperoxic 
alveolar growth–arrested rat lungs mimicking bronchopulmonary dysplasia proliferated less, showed decreased 
clonogenic capacity, and formed fewer capillary-like networks. Intrajugular administration of human cord blood–derived 
ECFCs after established arrested alveolar growth restored lung function, alveolar and lung vascular growth, and attenuated 
pulmonary hypertension. Lung ECFC colony- and capillary-like network-forming capabilities were also restored. Low 
ECFC engraftment and the protective effect of cell-free ECFC-derived conditioned media suggest a paracrine effect. 
Long-term (10 months) assessment of ECFC therapy showed no adverse effects with persistent improvement in lung 
structure, exercise capacity, and pulmonary hypertension.
Conclusions—Impaired ECFC function may contribute to arrested alveolar growth. Cord blood–derived ECFC therapy may 
offer new therapeutic options for lung diseases characterized by alveolar damage.  (Circulation. 2014;129:2144-2157.)
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absolutely critical for vascular development and embryonic 
survival. VEGF signaling contributes to normal lung devel-
opment, and early disruption of VEGF signaling leads to 
structural abnormalities seen in experimental and human BPD 
and emphysema. Angiogenic growth factor activation pro-
tects against O2-induced arrested alveolarization and stimu-
lates lung vascular growth in newborn rats.6,7 Compensatory 
lung growth following unilateral pneumonectomy stimulates 
pulmonary capillary endothelial cells to produce angiocrine 
growth factors that induce the proliferation of epithelial pro-
genitor cells to support alveolarization.8
Recent observations suggest that the lung microvascular endo-
thelium is enriched with resident progenitor cells that exhibit 
vasculogenic capacity.9 These highly proliferative cells resem-
ble the endothelial colony-forming cells (ECFCs) described in 
human peripheral and umbilical cord blood.10 The role of lung 
ECFCs during normal and impaired lung growth is unknown.
We hypothesized that ECFC-driven angiogenesis contrib-
utes to normal lung alveolar development, and ECFC sup-
plementation restores disrupted lung alveolar and vascular 
growth in hyperoxia-induced experimental BPD.
Materials and Methods
Expanded methods are available in the online-only Data Supplement. 
All procedures were approved by the Animal Health Care Committee 
of the University of Alberta. Human fetal tissue collection was 
reviewed by the Institutional Review Board at the University of New 
Mexico.
Lung ECFC Isolation and Culture
Human fetal lungs (n=3, 17–20 weeks gestational age) were col-
lected within 60 minutes after termination, washed in sterile 
 phosphate-buffered saline with antimicrobials, and suspended 
for further processing in Minimal Essential Medium-a with 10% 
fetal calf serum and antimicrobials. Rat lungs were collected 
at postnatal day (P) 14 (n=5/group). Under aseptic conditions, 
the peripheral rims of the lungs were cut out, chopped into 1- to 
2-mm2 pieces, and suspended in digestive solution (0.1 U collage-
nase and 0.8 U dispase/mL; Roche Applied Science, Laval, QC) 
at 37°C for 1 hour with intermittent shaking. The lung digest was 
strained through 70-mm and 40-mm cell strainers in tandem and 
washed twice with Dulbecco's modified Eagle medium (DMEM) 
plus 10% fetal calf serum, at 300g and 4°C for 10 minutes. After 
washing, the cells were resuspended in phosphate-buffered saline 
containing 0.1% (wt/vol) bovine serum albumin and incubated with 
 streptavidin-tagged Dynabeads (Dynal, Invitrogen, Burlington, 
ON) that were pretreated with biotinylated anti-rat or anti-human 
CD31 antibody (Abcam, Cambridge, MA). The Dynabead-tagged 
CD31-positive cells were selected by using a magnetic separa-
tor and plated in a 6-well plate (4000–5000 cells/well) precoated 
with rat tail collagen type I and placed in a 37°C, 5% CO2 humidi-
fied incubator. After 24 hours of culture, nonadherent cells and 
debris were aspirated, and adherent cells were washed once and 
added with complete Endothelial Growth Medium-2. Medium was 
changed daily for 7 days and then every other day up to 14 days. 
ECFC colonies appeared as a  well-circumscribed monolayer of 
cobblestone-appearing cells, between 5 and 14 days. ECFC colo-
nies were identified daily from day 5 and enumerated on day 7 by 
visual inspection by using an inverted microscope (Olympus, Lake 
Success, NY), under ×20 magnification. Individual ECFC colonies 
were marked with a fine-tipped marker and clonally isolated by 
using cloning cylinders (Fisher Scientific, Ottawa, ON) and plated 
in T25 flasks pretreated with collagen type I. On confluence, ECFCs 
were plated and expanded in type I collagen–coated T75 flasks. 
ECFCs between passages 4 and 8 were used for all experiments.
Dil-Acetylated Low-Density Lipoprotein Uptake 
and Ulex europaeus-Lectin Binding
Experiments were performed as previously described.10
Immunophenotyping of ECFCs
ECFCs were phenotyped by flow cytometry analysis.10
Retroviral Mediated Enhanced Green Fluorescent 
Protein Labeling of ECFCs
Rat lung ECFCs in passage 4 to 5 were incubated overnight with 
2 × 106 TU/mL of lentiviral vector and 7 μg/mL protamine sulfate 
in complete Endothelial Growth Medium-2. ECFCs in wells with 
uniform green fluorescence were trypsinized, expanded, and sorted 
for green fluorescence protein by using  fluorescent-activated cell 
sorting.
In Vitro Cell Viability Assay
ECFC viability was evaluated at various time points with the use of 
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
assay as previously described.11
Capillary-Like Network Formation in Matrigel
The formation of cordlike structures by ECFCs was assessed on 
Matrigel (BD Biosciences, Mississauga, ON) coated 96-well tissue 
culture plates as previously described.7
Single-Cell Clonogenicity
The FACSAria cell sorter (BD Biosciences, Mississauga, ON) was 
used to place 1 ECFC per well in a flat-bottomed 96-well tissue cul-
ture plate precoated with type I collagen and containing 200 μL of 
complete Endothelial Growth Medium-2. At day 14, Hoechst 33258 
(Sigma) was added at 3 μg/mL to each well for 10 minutes for nuclear 
detection. The culture plate was examined with a fluorescent micro-
scope at ×20 magnification, well by well, for the growth of endothe-
lial cells.
De Novo Angiogenesis in Vivo
ECFCs were loaded on collagen-fibronectin matrices and implanted 
subcutaneously in nonobese diabetic/severe combined immunodefi-
ciency mice to assess their capacity to contribute to de novo vasculo-
genesis as described.12
Oxygen-Induced BPD Model
We used 3 rodent models of oxygen-induced BPD. (1) For com-
parison of lung ECFC function, newborn Sprague Dawley rat 
pups were exposed to room air (21%; control group) or hyperoxia 
(95% oxygen; BPD group) from birth to P14 in sealed Plexiglas 
chambers (OxyCycler; BioSpherix, Lacona, NY) with continuous 
oxygen monitoring, and ECFCs were isolated at P14 for compara-
tive analysis.7 (2) To test the therapeutic potential of human cord 
blood–derived ECFCs, immune-compromised newborn rag−/− 
mice were exposed to 85% oxygen from P4 to P14. Human cord 
blood–derived ECFCs, isolated, expanded, and quality controlled 
as previously described,10 were administered at P14 through the 
jugular vein (105 cells/mouse in 100 μL of DMEM). Lungs were 
harvested at P28. For cell engraftment experiments, ECFCs were 
labeled before an injection with a red fluorophore (CellBrite 
Cytoplasmic Membrane Staining Kit, Biotium Inc, Hayward, 
CA). A subset of rag−/− mice was kept for long-term assess-
ment until 10 months of age. (3) In subsequent experiments, we 
used RNU nude rats (exposed to 95% oxygen from P4 to P14 
and injected with 2.5×105 cells/rat in 100 μL of DMEM) to test 
if human cord blood–derived ECFC treatment restored resident 
lung ECFC function.
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Lung Morphometry
Lungs were fixed and alveolar structures were quantified on a motor-
ized microscope stage (Leica CTRMIC and openlab software, 
Quorum Technologies; Guelph, ON) by using the mean linear inter-
cept as previously described.7
Immunohistochemistry
von Willebrand Factor–positive lung capillaries (30–100 μm) were 
quantified on a motorized microscope stage.
Right Ventricular Hypertrophy
The right ventricle free wall was separated from the left ventricle and 
the septal wall. The tissue was dried overnight and weighed the fol-
lowing day.13
Echocardiography
All evaluations of pulmonary artery flow were performed with a 
(maximal) sweep speed of 200 mm/s. Pulsed-wave Doppler of pul-
monary outflow was recorded in the parasternal view at the pulmo-
nary valve level. The pulmonary arterial acceleration time (PAAT) 
was measured from the beginning of the pulmonary flow to its onset 
and normalized with heart rate for comparisons as described.13
Lung Function Testing
Tests were performed on anesthetized and paralyzed animals with the 
use of Flexivent (Scireq, Montreal, QC, Canada) as described.14
Real-Time Polymerase Chain Reaction
Real-time polymerase chain reaction was performed on frozen lungs 
from 3 animals/group harvested at various time points after injection 
as described.15
ECFC-Derived Conditioned Medium Experiments
Conditioned medium (CdM) was obtained as described.15 On prepa-
ration, CdM was pooled, frozen at −80°C and thawed right before 
use. Control cell CdM was obtained from human umbilical vein 
endothelial cells (HUVECs).
In vitro, AT2 were isolated from time-dated fetal day 19.5 rat lungs 
as described by using serial differential adhesions to plastic and 
 low-speed centrifugations.16 For wound-healing assays, a cell mono-
layer was scraped with a p200 pipette tip and media replaced with 
CdM or DMEM as described.16
In vivo, CdM was administered daily to newborn rats exposed to 
hyperoxia through intraperitoneal injections at the dose of 7 μL/g15 
from P4 to P21 and lungs were harvested at P22.
Exercise Capacity
Mice were run according to a predetermined protocol.15
Statistical Analysis
Values are expressed as means±standard error of the mean. Statistical 
comparisons were made with 1-way analysis of variance. Time course 
studies were analyzed by using repeated-measures analysis of variance. 
Post hoc analysis used Fisher probable least significant difference test 
(Statview 5.1; Abacus Concepts, Berkeley, CA). A value of P<0.05 was 
considered statistically significant. All P values were 2-sided, and no 
adjustment for multiple comparisons was made. All end points were 
assessed by investigators blinded to the experimental groups.
Results
Human Fetal Lung Harbors ECFCs With  Self-
Renewal, High Proliferative Potential, and de Novo 
Blood Vessel Formation Capacity
CD31-positive selected cells isolated from human fetal lung 
tissue yielded cobblestone-like colonies at between 4 and 
14 days in culture (Figure 1A). These late-outgrowth colo-
nies demonstrated basic endothelial cell characteristics such 
as ingestion of Dil-acLDL, binding U europaeus-lectin 
(Figure 1B) and tube formation in Matrigel (Figure 1C). 
Further phenotypic characterization revealed the expres-
sion of  endothelial-specific cell surface markers includ-
ing CD31, CD105 (endoglin), CD144 (VE-cadherin), and 
CD146 (M-CAM; Figure 1D). Human ECFCs were nega-
tive for monocyte/macrophage–specific CD14 and hemato-
poietic cell–specific CD45 (Figure 1D) and, thus, display an 
 ECFC-like phenotype, consistent with the phenotype of circu-
lating human cord blood ECFC.17
In single-cell clonogenic assays, lung endothelial cells gen-
erated colonies from single-plated cells: 6.0±1.0% formed 
colonies with 50 to 500 cells (low proliferative potential) and 
7.6±2.8% formed >500 cells (high proliferative potential, 
HPP) in 3 independent experiments (Figure 1E). On replat-
ing, ECFCs generated secondary colonies with similar fre-
quency (6.0±1.0% colonies with 50–500 cells and 8.0±2.0% 
formed >500 cells) in 3 independent experiments (Figure 1F). 
Thus, the human lung endothelial cells displayed the clonal 
 self-replenishing capacity.
In collagen-fibronectin–loaded matrices implanted subcu-
taneously in nonobese diabetic/severe combined immunode-
ficiency mice, human lung ECFCs formed de novo capillaries 
identified by antibody specific for human CD31 that connected 
with the host vasculature as demonstrated by the presence of 
circulating red blood cells in the capillary lumen (Figure 1G). 
Together these observations confirm the existence of resident 
ECFCs with properties similar to cord blood ECFC in the 
developing human lung.
Hyperoxia Impairs Human Lung ECFC Function
Hyperoxia is 1 deleterious factor contributing to BPD. To mimic 
the disease condition in vitro, we exposed human lung ECFCs 
to 40% hyperoxia for 24 hours. ECFCs exposed to hyperoxia 
formed fewer capillary-like structures in Matrigel in compari-
son with ECFCs exposed to room air (Figure 1H) and generated 
fewer HPP ECFC colonies in comparison with ECFCs cultured 
in room air (Figure 1I). These results are consistent with previ-
ous studies reporting disrupted VEGF-nitric oxide signaling in 
cord blood ECFC exposed to hyperoxia in vitro and suggests 
impaired ECFC function may be associated with decreased 
lung vascular growth and arrested alveolarization in BPD.
Lung ECFC Function Is Impaired in Experimental 
Hyperoxia-Induced BPD in Newborn Rats
To further investigate this hypothesis, we explored lung ECFC 
function in a well-established hyperoxia-induced neonatal rat 
model of arrested alveolar growth mimicking some of the his-
tological features seen in human BPD.
First, we show that, similar to the human fetal lung, the 
neonatal rat lung harbors ECFCs that form cobblestone-like 
colonies within 7 to 14 days, with basic endothelial cell charac-
teristics (Dil-acLDL ingestion and U europaeus-lectin binding) 
and tubelike formation in Matrigel (Figure 2A through 2C). 
The lung ECFC also displayed endothelial-specific cell surface 
markers (CD31, VEGFR2, and von Willebrand Factor) but did 
not express hematopoietic cell–specific CD45, CD14, or CD133 
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(Figure 2D). In single-cell clonogenic assays, rat ECFCs gener-
ated low proliferative potential and HPP colonies from single-
plated cells and secondary HPP on replating (Figure 2E).
Rat lung ECFCs also formed de novo capillaries when 
implanted subcutaneously in nonobese diabetic/severe com-
bined immunodeficiency mice in collagen-fibronectin–loaded 
matrices (Figure 2F).
Next, we compared the function of ECFCs extracted from 
a neonatal rat model mimicking BPD. Following 2 weeks of 
exposure of neonatal rats to hyperoxia (95% O2), the lungs of 
newborn rats develop a consistent and irreversible histological 
pattern of alveolar simplification and vascular paucity, charac-
teristic of human BPD (Figure 3A).
When plated at equal densities and cultured in identical 
conditions, rat lung ECFCs from the hyperoxia-exposed rats 
showed reduced cell growth (Figure 3B).
ECFCs from hyperoxia-exposed rat lungs formed 
fewer cordlike endothelial networks in comparison with 
10x
10
x
20x
UlexDi-Ac-LDL Hoechst
10x
CD31 CD146CD105 CD144 CD14 CD45
0
x
41d0d
Human Fetal
Lung ECFCs
Subcutaneous 
implant
Implant
vascularization
D
A B C
G
2-50 cells/well 50-500 cells/well >500 cells/well
<50 50-500 >500
M
ea
n 
N
o.
 o
f C
ol
on
ie
s
0
5
10
15
20
25
(3 independent trials)
E
Generation 1
0
5
10
15
20
25
<50 50-500 >500
M
ea
n 
N
o.
 o
f C
ol
on
ie
s
(3 independent trials)
F
Generation 2
0
5
10
15
20
25
RA O2
2-50 cells/well 50-500 cells/well >500 cells/well
RA O2
Number of Intersections
n=5 for both groups
*P<0.05 vs. RA
H
I
*
N
o.
 o
f c
ol
on
ie
s p
er
 9
6-
w
el
l p
la
te
0
10
20
30
40 RA
O2
<50 50-500 >500
*
* P < 0.05 vs. RA
3 Independent trials in each group
Figure 1. ECFCs exist in the developing human fetal lung and are perturbed by hyperoxia. A, Phase-contrast microscopy showing 
characteristic cobblestone-like colonies of CD31-positive cells obtained by beads isolation. B, These cells demonstrate Dil-acLDL uptake 
(red) within 4 hours of incubation and Ulex europaeus-lectin binding (green) within 1 hour of incubation after fixation. Counterstaining with 
Hoechst 33258 (blue) illustrates that all adherent cells are positive for LDL uptake and U europaeus (Ulex)-lectin binding.  
C, These cells form tube-like structures when suspended in Matrigel. D, Fluorescent-activated cell sorting. Isolated cells are positive for 
endothelial-specific cell surface antigens CD31, CD105 (endoglin), CD144 (VE-cadherin), CD146 (M-CAM), and negative for monocyte/
macrophage–specific CD14 and hematopoietic cell–specific CD45. Filled gray histograms represent antigen staining with negative 
isotype controls overlaid in white. All experiments were performed in triplicate. E, Single-cell clonogenic assay. Single cells are capable of 
giving rise to clusters (up to 50 cells) or colonies 50 to 500 cells (low proliferative potential, LPP) or more than 500 cells (high proliferative 
potential, HPP) in 96-well plates when plated at a seeding density of 1 cell per well. Results represent the mean±standard error of mean 
of 3 independent experiments. F, On replating, HPP ECFCs were able to form clusters or secondary colonies with LPP and HPP.  
G, Subcutaneous Matrigel Plug Assay. Human fetal lung ECFCs form blood vessels de novo when seeded in fibronectin-collagen 
plugs (106 ECFCs per implant) and implanted subcutaneously into the flanks of NOD/SCID mice. Fourteen days postimplantation, the 
cellularized implants were excised, paraffin embedded, and stained with hematoxylin and eosin and anti-human CD31 (brown). Black 
arrows indicate red blood cell–perfused anti-human CD31+ vessels within the gel implant. H, Hyperoxia impairs network formation in 
vitro. Human fetal lung ECFCs exposed to 40% hyperoxia in vitro show a significant decrease in the number of intersects in comparison 
with RA-exposed ECFCs (n=5 for each group, *P<0.05). I, Comparative single-cell clonogenic assay. Human fetal lung ECFC exposed 
to 40% hyperoxia in vitro and plated in 96-well plates at a seeding density of 1 cell per well formed clusters and gave rise to colonies 
with LPP, but formed significantly fewer HPP than RA-exposed ECFCs (*P<0.05, 3 independent experiments). Dil-acLDL indicates  Dil-
acetylated low-density lipoprotein; ECFC, endothelial colony-forming cell; LDL, low-density lipoprotein; NOD/SCID, nonobese diabetic/
severe combined immunodeficiency; and RA, room air.
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controls as assessed by total cord length by 32.7±11.8% 
(P<0.05) and number of intersects by 48.2±5.3% (P<0.05; 
Figure 3C).
In single-cell clonogenic assays, 23.6±2.5% of single 
plated ECFCs from the control group versus only 9.3±3.2% 
of ECFCs from the hyperoxia group were capable of form-
ing HPP colonies containing >500 cells each (P<0.05; 
Figure 3D). No significant difference between the groups 
was observed in the percentage of cells that formed low 
proliferative potential colonies containing <50 cells or 50 
to 500 cells.
Together, these findings suggest a functional deficiency 
in the ECFCs isolated from lungs of hyperoxia-exposed 
newborn rats. Because angiogenesis contributes to normal 
alveolarization and oxygen-induced arrested alveolar-
ization is associated with decreased ECFC function, we 
investigated the therapeutic potential of human cord blood–
derived ECFCs to restore normal alveolarization in this 
model.
Human Cord Blood-Derived ECFCs Reverse 
Alveolar Growth Arrest, Preserve Lung Vascularity, 
and Attenuate Pulmonary Hypertension in 
Hyperoxia-Induced BPD in Newborn Rodents
Exposure of newborn rag−/− mice to hyperoxia (85% O2) from 
P4 to P14 (Figure 4A) increased lung compliance (Figure 4B) 
and induced a histological pattern reminiscent of human BPD, 
characterized by fewer, enlarged alveolar structures (mean 
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Figure 2. ECFCs exist in the developing rat lung. A, Phase-contrast microscopy showing characteristic cobblestone-like colonies of 
CD31-positive cells obtained by beads isolation. B, These cells demonstrate Dil-acLDL uptake (red) within 4 hours of incubation and 
Ulex europaeus-lectin binding (green) within 1 hour of incubation after fixation. Counterstaining with Hoechst 33258 (blue) illustrates 
that all adherent cells are positive for LDL uptake and U europaeus (Ulex)-lectin binding. C, These cells form tube-like structures when 
suspended in Matrigel. D, Fluorescent-activated cell sorting. Isolated endothelial cells are positive for endothelial-specific cell surface 
antigens CD31, vWF, and VEGFR2 and negative for monocyte/macrophage–specific CD14 and hematopoietic cell–specific CD45 and 
CD133. E, Single-cell clonogenic assay. Rat lung endothelial cells are capable of giving rise to clusters (up to 50 cells) or colonies 50 
to 500 cells (low proliferative potential, LPP) or >500 cells (high proliferative potential, HPP) in 96-well plates when plated at a seeding 
density of 1 cell per well. Results represent the mean±standard error of mean of 3 independent experiments. On replating, HPP ECFCs 
were able to form clusters or secondary colonies with LPP and HPP. F, Subcutaneous Matrigel Plug Assay. Rat lung ECFCs form blood 
vessels de novo when seeded on fibronectin-collagen plugs (106 ECFCs per implant) and implanted subcutaneously into the flanks 
of NOD/SCID mice. Fourteen days postimplantation, the cellularized implants were excised, paraffin embedded, and stained with 
hematoxylin and eosin and anti-human CD31 (brown). The arrow points to a rat endothelial cell; the rat endothelial cell lines a vessel filled 
with mouse red blood cells indicating that the rat endothelial cells have connected with the mouse circulation. The arrowhead points to a 
murine endothelial cell lining a mouse blood vessel. Dil-acLDL indicates Dil-acetylated low-density lipoprotein; ECFC, endothelial  colony-
forming cell; LDL, low-density lipoprotein; and NOD/SCID, nonobese diabetic/severe combined immunodeficiency.
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linear intercept 41±2.3 versus 25.6±1.9 in room-air controls, 
P<0.05; Figure 4C and 4D). Intrajugular administration of cord 
blood–derived ECFCs at P14 after established alveolar growth 
arrest, significantly improved lung compliance (Figure 4B) and 
alveolar architecture (mean linear intercept 30.3±1.6, P<0.05; 
Figure 4C and 4D). ECFCs had no adverse effect on lung func-
tion and structure in room air–housed control animals.
Hyperoxia-exposed mice had decreased lung vascular 
growth (mean number of blood vessels/high power field 
3.5±0.3 versus 2.2±0.4; Figure 5A and 5B) and exhibited 
pulmonary hypertension as assessed by echo Doppler (PAAT 
11.4±0.4 versus 14.9±1.6 in room-air controls, P<0.05) and 
right ventricle hypertrophy (right ventricle/left ventricle plus 
septum ratio 0.35±0.05 versus 0.22±0.06 in room-air controls, 
P<0.01; Figure 5C). ECFC therapy restored PAAT almost to 
control levels (14.1±2) and significantly reduced right ven-
tricle hypertrophy (right ventricle/left ventricle plus septum 
ratio 0.26±0.03; Figure 5D).
Similarly, ECFC therapy restored normal alveolar architec-
ture (Figure IA in the online-only Data Supplement), lung vas-
cular growth (Figure IB in the online-only Data Supplement) 
in newborn RNU rats that were exposed to 95% hyperoxia 
from P4 to P14 (immunocompromised rat BPD model). In 
addition, ECFC therapy significantly attenuated right ventricle 
hypertrophy in hyperoxia-exposed RNU rats (Figure ID in the 
online-only Data Supplement).
Figure 3. Rat lung ECFC function is perturbed in hyperoxia-induced experimental BPD in newborn rats. A, Schematic describing the rat 
model of hyperoxia-induced BPD. Newborn rats are housed in 95% O2 from postnatal day (P) 4 to P14 and studied in comparison with 
room air (RA)–raised control rats. Exposure of rat pups to hyperoxia during the alveolar stage of lung development results in arrested 
alveolar growth characterized by larger and fewer alveolar structures as shown in hematoxylin and eosin–stained representative lung 
slides. ECFCs were isolated from RA and hyperoxia-exposed rat lungs on P14, and their proliferative, clonogenic, and vessel-forming 
potentials were assessed. B, MTT Assay. Lung ECFCs form RA and hyperoxic animals were plated at equal cell densities and cultured 
under identical culture conditions. ECFCs from the hyperoxia-exposed group showed decreased cell growth as assessed by MTT assay 
(n=6, P<0.05 on days 12 and 16, P<0.01 on day 8, and P<0.001 on day 20). C, Matrigel assay. Quantitative assessment of the ability to 
form tube-like structures on Matrigel reveals a significant decrease in the total cord length and the number of intersects in the  hyperoxia-
exposed ECFCs in comparison with RA ECFCs (n=6 for each group, *P<0.05). D, Comparative single-cell assay. Colony-forming potential 
of single-cell–plated rat lung ECFCs was assessed by measuring the percentage of single ECFCs capable of generating colonies after 
14 days in culture. Significantly fewer ECFCs from the hyperoxia group are capable of generating colonies with ≥500 cells in comparison 
with RA controls (n=6 lungs/group, *P<0.05). BPD indicates bronchopulmonary dysplasia; ECFC, endothelial colony-forming cell; and 
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide.
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ECFC Engraftment and Contribution to Lung 
Neovascularization
Quantification of human ECFCs by the use of quantitative 
reverse transcriptase-polymerase chain reaction showed a low 
rate of engraftment in recipient lungs with a drastic decrease 
in detected human Alu sequences from the first day after injec-
tion to almost undetectable levels within 3 days (Figure 6A). 
Fourteen days after fluorescent-labeled ECFC administration, 
very few cells were found in the lung (Figure 6B). However, 
when lung ECFCs were isolated from RNU rats and tested for 
clonogenic capacity, resident lung ECFCs from the treated 
hyperoxia group were capable of forming significantly more 
HPP colonies than the untreated hyperoxia-exposed group 
(P<0.05; Figure IIA in the  online-only Data Supplement). In 
addition, lung ECFCs from the treated animals formed more 
extensive endothelial networks than the untreated animals in 
the hyperoxia group as assessed by cord length and number 
of intersects (P<0.05; Figure IIB in the online-only Data 
Supplement).
Paracrine Effect of Human Cord  
Blood–Derived ECFCs
Given the low engraftment of ECFCs at the doses administered 
in these studies and evidence that some endothelial progenitor 
cells (EPCs) secrete factors that promote tissue repair,18 we 
hypothesized that ECFCs may also exert a paracrine activity 
that mediates the reparative response in the lung. To verify 
this, we assessed the effect of cell-free human cord blood–
derived ECFC CdM in vitro and in vivo.
In vitro, we assessed the protective effects of  ECFC-CdM 
by using 2 experimental models representing the epithelial 
and endothelial compartments of lung alveoli. First, con-
fluent monolayers of AT2 cells were subject to a pipette 
tip–inflicted scratch injury in the presence of DMEM, 
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Figure 4. Human umbilical cord blood ECFC therapy improves lung function and reverses alveolar growth arrest in hyperoxia-exposed 
newborn mice. A, Experimental design. Newborn rag−/− mice were housed in room air (RA) or 85% O2 from postnatal day (P) 4 to P14.  
At P14, mice were treated with intrajugular injections of human umbilical cord blood–derived ECFCs and housed in RA until the 
assessment of end points on P28. B, Lung function testing. Untreated mice exposed to hyperoxia had significantly increased lung 
compliance in comparison with RA and ECFC-treated RA controls (n=4–7, P<0.05). Lung compliance was significantly improved in 
hyperoxia-exposed mice treated with ECFCs in comparison with untreated hyperoxia-exposed controls (P<0.05). C, Representative 
hematoxylin and eosin–stained lung sections showing larger and fewer alveoli in untreated hyperoxia-exposed (O2) lungs in comparison 
with control mice housed in RA at P28. Intrajugular administration of ECFCs in O2-exposed animals preserved alveolar growth. ECFCs 
did not affect lung structure in control RA mice. D, Quantitative assessment of alveolar architecture by mean linear intercept confirms 
the protective effect of ECFCs on alveolar growth (n=5/group, *P<0.05). BPD indicates bronchopulmonary dysplasia; ECFC, endothelial 
colony-forming cell; and hUCB, human umbilical cord blood.
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HUVEC-CdM, or ECFC-CdM. At 12 hours, AT2 cell 
wound closure was significantly higher with ECFC-CdM 
than with DMEM and HUVEC-CdM (Figure 7A and 
7B). Second, human fetal lung ECFCs were suspended in 
serum-free Matrigel overlaid with DMEM, HUVEC-CdM, 
or  ECFC-CdM and incubated in room air or 95% oxygen. 
At 6 hours, hyperoxia significantly decreased endothelial 
cord–like structure formation in DMEM and HUVEC-CdM, 
Figure 5. Human umbilical cord ECFCs improve lung angiogenesis and prevent pulmonary hypertension in hyperoxia-exposed newborn 
mice. A and B, Effects of ECFC treatment on pulmonary vessel density assessed on lung slides stained with von Willebrand Factor at 
P28. The pulmonary vessel density of 30 to 100μm sized blood vessels per 10 high-power fields (×40) was significantly decreased in 
the lungs of O2-exposed animals in comparison with RA. Intrajugular injection of ECFCs significantly improved pulmonary vessel density 
(n=5/group, *P<0.01). C, Pulmonary arterial acceleration time (PAAT) was significantly decreased in O2-exposed animals in comparison 
with controls. Intrajugular ECFCs restored the PAAT almost to control levels (n=4–6/group, *P<0.01). D, Hyperoxia-exposed mice had 
significant RVH as indicated by the increase in right ventricle/left ventricle plus septum (RV/LV+S) ratio in comparison with controls. ECFC 
therapy significantly reduced RVH (n=4–9/group, *P<0.01). ECFC indicates endothelial colony-forming cell; HPF, high-power field; RA, 
room air; and RVH, right ventricle hypertrophy. 
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Figure 6. Low engraftment rate after 
intrajugular injection of human umbilical 
cord ECFCs. A, Quantitative RT-PCR 
for human Alu sequences in the lung 
revealed a rapid decline during the 
first day after injection. Human DNA 
became almost undetectable 3 days 
after injection. B, Representative 
frozen lung section at P21 depicting 
rare fluorescent-labeled ECFCs. ECFC 
indicates endothelial colony-forming 
cell; and RT-PCR, reverse  transcriptase-
polymerase chain reaction.
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Figure 7. Paracrine effect of human umbilical cord ECFCs. A, Representative confluent monolayers of freshly isolated rat alveolar type 
2 epithelial cells (AT2) damaged by the use of a pipette tip, washed to remove damaged cells, and treated with DMEM, ECFC-derived 
conditioned medium (CdM) or HUVEC CdM. B, The percentage of wound closure showed that ECFC CdM accelerated AT2 wound 
closure in comparison with DMEM and HUVEC CdM (n=6/group, *P<0.05). C, Representative endothelial network formation assay on 
Matrigel of human fetal lung ECFCs treated with DMEM, ECFC-derived CdM or HUVEC CdM in room air (RA) and hyperoxia (O2).  
D, Quantitative assessment of cordlike structure formation shows a significant decrease in the number of intersects in hyperoxia in 
DMEM and HUVEC CdM–treated ECFCs in comparison with RA-exposed ECFC. ECFC CdM preserved the number of intersects in 
hyperoxia (n=3–6/group, *P<0.05). E, Representative hematoxylin and eosin section showing arrested alveolar growth in O2-exposed 
newborn rats in comparison with RA controls. ECFC CdM significantly preserved alveolar growth. F, Quantitative assessment of the mean 
linear intercept confirms the protective effect of ECFC CdM on alveolar growth (n=6/group, *P<0.001). G, Mean data showing decreased 
pulmonary vessel density in O2-exposed newborn rats in comparison with RA controls as assessed by the number of barium-filled 
pulmonary vessels. ECFC CdM significantly attenuated the loss of pulmonary vessels in hyperoxia (n=5/group, *P<0.01). H, Pulmonary 
arterial acceleration time (PAAT) was significantly decreased in O2-exposed animals in comparison with controls. ECFC CdM preserved 
the PAAT in comparison with untreated O2-exposed animals (n=5–6/group, *P<0.05). I, Hyperoxia-exposed rats had significant RVH as 
indicated by the increase in right ventricle/left ventricle plus septum (RV/LV+S) ratio in comparison with controls. ECFC CdM significantly 
reduced RVH in comparison with untreated O2-exposed animals (n=5–6/group, *P<0.05). DMEM indicates Dulbecco's modified Eagle 
medium; ECFC, endothelial colony-forming cell; HUVEC, human umbilical endothelial cell; and RVH, right ventricle hypertrophy.
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whereas ECFC-CdM significantly preserved ECFC network 
formation (Figure 7C and 7D).
In vivo, ECFC-CdM was administered as daily intraperitoneal 
injections from P4 to P21 to neonatal rats exposed to hyperoxia. 
CdM therapy preserved alveolar growth (Figure 7E and 7F), lung 
vascular growth (Figure 7G), and attenuated pulmonary hyper-
tension as assessed by the PAAT and right ventricular hypertro-
phy (Figure 7H and 7I). ECFC-CdM had no adverse effects on 
lung structure and lung vascularity in room-air control animals.
Long-Term Effects of ECFC Therapy
Intrajugular delivery of ECFCs at P14 appeared safe and effi-
cient up to 10 months of life. Air spaces remained enlarged 
(Figure 8A and 8B, and exercise capacity (Figure 8C) and 
PAAT (Figure 8D) remained perturbed in hyperoxic-exposed 
animals in comparison with room-air controls. In contrast, 
hyperoxic-exposed neonatal mice that had received ECFCs in 
the neonatal period exhibited preserved alveolar architecture 
(Figure 8A and 8B), significantly improved exercise capac-
ity (Figure 8C) and PAAT (Figure 8D) at 10 months of age. 
Control room air–housed animals treated with ECFCs showed 
no alterations in any of these parameters. Other organs includ-
ing the brain, heart, liver, kidney, and spleen had no signs of 
impaired architecture (data not shown).
Discussion
Here, we show that the developing human and rat lung harbors 
resident ECFCs capable of self-renewal and de novo vessel 
formation in vivo. We also provide evidence that hyperoxia 
perturbs human and rat lung ECFC function in vitro and in 
vivo in experimental oxygen-induced BPD, respectively. 
Furthermore, exogenous, human cord blood–derived ECFCs 
restore normal lung alveolar and vascular growth and func-
tion, diminish pulmonary hypertension, and restore resi-
dent lung ECFC function in this model in comparison with 
control animals. This effect is mediated through a paracrine 
effect. The therapeutic benefit persisted at 10 months with 
no adverse effects on lung structure and exercise capacity in 
 hyperoxia-exposed animals.
Increasing evidence suggests that blood vessels contrib-
ute to normal lung growth as opposed to passively following 
the development of the airways.5 This has led to the current 
working hypothesis that the preservation of vascular growth 
and endothelial survival promotes alveolar growth and 
sustains the architecture of the alveoli. The consistent asso-
ciation between arrested alveolar development and impaired 
capillary formation in human and experimental BPD and 
the demonstration that angiogenic growth factors promote 
normal alveolar development and repair further support this 
finding. Thus, if angiogenic growth factors and adequate lung 
vascularization contribute to lung development and integrity, 
then circulating or resident ECFCs are appealing candidate 
cells likely to be involved in the same mechanisms. The 
isolation of a circulating cell that gives rise to cells appear-
ing  endothelial-like in vitro and with the potential to incor-
porate at sites of neoangiogenesis in vivo by Asahara et al19 
challenged the paradigm that vasculogenesis is a process 
restricted to embryonic development and opened exciting 
new therapeutic avenues. A current limitation is the ability 
to define an EPC based on a set of markers that can unam-
biguously identify this cell type. To date, at least 3 different 
methodologies exist for the isolation of EPCs. Schematically, 
EPCs appear to represent 2 distinct cell populations: the 
minimally proliferative but proangiogenic hematopoietic or 
macrophage-like phenotype (that includes circulating angio-
genic cells and colony-forming unit Hill colonies) and the 
highly proliferative nonhematopoietic phenotype (ECFCs).12 
Based on their timing of emergence in culture, these popula-
tions have also been described as early- and late-outgrowth 
EPCs, respectively.20 ECFCs, which are phenotypically indis-
tinguishable from cultured endothelial cells, demonstrate 
high proliferative potential and the capacity for self-renewal 
and de novo vessel formation.21,22 ECFCs reside throughout 
the vascular endothelium contributing to vascular integrity 
and are mobilized into a circulating pool of endothelial pro-
genitors, putatively involved in neovasculogenesis via tissue 
recruitment and homing.21 Recently, Alvarez et al9 described 
a population of resident pulmonary microvascular EPCs in 
adult rat lungs that display a high proliferative potential and 
are capable of de novo angiogenesis in vivo. These cells 
resemble the ECFCs previously isolated from the periph-
eral circulation and in human umbilical cord blood. Similar 
cells have now been described in the mouse23 pulmonary 
circulation. This suggests that ECFCs could be the primary 
progenitor population participating in neovasculogenesis in 
the lung. The existence of these resident lung ECFCs in the 
developing lung and their role in arrested alveolar growth in 
BPD is unknown. We reasoned that ECFCs dysfunction could 
Figure 7. Continued.
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underlie the pathogenesis of diseases such as BPD, character-
ized by disrupted vascular growth.
We adopted a procedure based on the already existing pro-
tocol for recovering circulating ECFCs from bone marrow 
or peripheral blood10 to demonstrate the presence of resident 
ECFCs in fetal human and neonatal rat lung. These cells dis-
played the stringent characteristics of ECFCs including (1) the 
ability to generate colonies with ≥500 daughter cells derived 
from cultured single cells and (2) some of the clonogenic 
cells are capable of self-renewal, and (3) the capacity to form 
vessels de novo, when impregnated in  collagen-fibronectin 
gels and implanted subcutaneously in recipient immunode-
ficient mice.
Given the importance of angiogenesis in normal alveo-
lar growth, we hypothesized that ECFC function would 
be impaired in disease conditions associated with arrested 
alveolar growth such as BPD. Earlier observations reported 
on the susceptibility of cord blood–derived ECFCs to oxi-
dant damage.24 Furthermore, cord blood–derived ECFCs 
are lower in number in preterm infants who subsequently 
develop BPD versus those who do not develop BPD.25,26 
Here, we show that resident human lung ECFCs exposed to 
hyperoxia in vitro and rat ECFCs isolated from the lung of a 
hyperoxia-induced BPD model that display arrested alveo-
lar growth were significantly hampered in their ability to 
proliferate, form vascular networks in vitro, and generate 
colonies with HPP in comparison with ECFCs isolated from 
control lungs. Although there are no specific cell surface 
markers to identify the resident ECFC within the vascular 
endothelial intima in vivo, it is interesting that endothelial 
replacement or expansion within the aorta has long been 
known to emerge within clusters of endothelial cells rather 
than a dispersed pattern during normal embryonic growth or 
in animals with hypertension.27,28 Confirmation of the ECFC 
Figure 8. Long-term safety and efficacy of ECFC cell therapy. A, Representative hematoxylin and eosin–stained lung sections at  
10 months of age shows persistent alveolar simplification in hyperoxia-exposed animals in comparison with lungs from rats housed in 
room air (RA). Oxygen-exposed animals treated with ECFCs have improved lung histology. B, The mean linear intercept confirms arrested 
alveolar growth in untreated O2-exposed animals in comparison with RA and RA+ECFC–treated animals and preserved alveolar structure 
with ECFC therapy in comparison with untreated O2-exposed animals (n=3–6/group, *P<0.05). C, Oxygen-exposed animals experienced 
reduced exercise capacity in comparison with RA-housed animals. Oxygen-exposed animals treated with ECFC had improved exercise 
capacity (n=3–6 animals/group, *P<0.05). D, Oxygen-exposed animals had decreased pulmonary arterial acceleration time (PAAT) in 
comparison with RA and RA+ECFC animals. Oxygen-exposed animals treated with ECFC had improved PAAT in comparison with 
untreated O2-exposed animals (n=3–6 animals/group, *P<0.05). E, Representative lung section of an ECFC-treated mouse lung at 10 
months of age showing no presence of CD31-positive structures. In contrast, CD31 staining is abundant in a human adult lung. ECFC 
indicates endothelial colony-forming cell.
 by guest on D
ecem
ber 22, 2016
http://circ.ahajournals.org/
D
ow
nloaded from
 
Alphonse et al  Endothelial Colony-Forming Cells for Lung Repair  2155
within the vascular endothelial intima will require further 
work to identify a unique and specific marker.
These data formed the rationale for testing the therapeutic 
potential of umbilical cord blood–derived ECFC supplemen-
tation in experimental BPD. Here, we provide the first evi-
dence for the therapeutic benefit of ECFCs in restoring lung 
vascular and alveolar growth and lung function, as well, in 
an established model of BPD. ECFCs also attenuated pul-
monary hypertension, a complication commonly associated 
with severe BPD. In addition, treatment with cord blood–
derived ECFCs restored colony-forming and capillary-like 
 network-forming capabilities of resident lung ECFCs of new-
born rats with experimental BPD. These data are consistent 
with the beneficial effect of angiogenic factors in experimen-
tal BPD29–31 and underscore the therapeutic benefit of promot-
ing lung angiogenesis to repair the lung. Altogether, these 
observations suggest an increased susceptibility of ECFCs 
in the developing lung to hyperoxia that may contribute to 
impaired lung vascular and alveolar growth in BPD and that 
ECFC supplementation represents a promising strategy for 
lung repair.
In this study, we have used ECFCs derived from human 
cord blood to document the therapeutic effect of these cells 
in a model of impaired lung development. This clinically rele-
vant source of ECFCs appears particularly appealing for treat-
ing neonatal diseases. To test ECFCs of human origin we used 
immunodeficient rag−/− mice, in which hyperoxia-mediated 
lung injury appeared less pronounced. Practical constraints 
in obtaining ECFCs from the rat cord blood limited us from 
using the more robust model of in newborn Sprague-Dawley 
rats. Despite this limitation, the demonstrated findings are 
consistent and convincing with regard to the therapeutic effect 
of ECFCs in BPD.
In this study, we administered ECFCs after established 
arrested alveolar growth and after hyperoxic exposure. The 
rationale was based on previous in vitro studies suggesting 
that hyperoxia impairs cord blood–derived ECFC function.24,32
Lung injury in neonatal mice exposed to hyperoxia is 
also associated with decreased early-outgrowth EPCs33 
and can be overcome by bone marrow–derived angio-
genic cell infusion.34 Further evidence for the role of EPCs 
in lung repair is provided by experimental and clinical 
data showing that (1) bone marrow–derived EPCs attenu-
ate  lipopolysaccharide-induced acute lung injury35 and 
 elastase-induced emphysema,36,37 (2) EPCs are higher in 
patients with acute lung injury than in healthy control sub-
jects,38 and (3) the increase in circulating EPCs correlates 
with improved outcome and illness severity and improved 
survival in acute38,39 and chronic40 lung disease, suggesting a 
prognostic role similar to ischemic heart disease.
Very few engrafted cells were detected by immunofluo-
rescence and analysis of human-specific Alu sequences. We 
did not pursue a dose-dependent study to find a concentra-
tion of ECFC that engrafted into regenerating vasculature in 
this model. Others have noted that human ECFCs can form 
up to 27% of the vascular endothelium in recovering ischemic 
muscle tissue of nude mice subjected to a hind limb ischemic 
injury.41 Additional work may determine that higher doses of 
administered human cells may lead to sustained engraftment. 
Alternatively, this observation may suggest that, similar to 
other cell-based strategies including early outgrowth EPCs 
and mesenchymal stromal cell therapy, ECFCs exert their ther-
apeutic benefit mainly through a paracrine activity. This para-
crine activity is supported by the protective effect of  cell-free 
ECFC-derived CdM on alveolar epithelial cell wound healing 
and human lung ECFC vascular network formation in vitro. 
As well, in vivo, ECFC-derived CdM restored alveolar and 
lung vascular growth comparable to whole-cell therapy.
In our in vivo studies, CdM was administered as daily intra-
peritoneal injections from P4 to P21 with the reasoning that 
repeated dispensation would be necessary to ensure continu-
ous availability of protective factors. With cell therapy, on the 
other hand, we expected a more sustained release of protective 
factors from the transfused cells even after a single intrave-
nous dose. However, recent observations suggest that a single 
injection of CdM may be sufficient to prevent oxygen-induced 
lung injury in neonatal mice.1,2 The biologically active com-
ponent of mesenchymal stromal cell-derived CdM seems to 
be contained in exosomes, membrane-derived nanoparticles, 
as recently demonstrated in a hypoxia-induced model of pul-
monary hypertension.42 It is likely that ECFCs, as many other 
cells, produce exosomes. Whether these exosomes can be 
used as biomarkers or therapeutic tools remains to be studied.
A concern with cell-based therapy, especially in the neo-
nate, is the risk of long-term adverse effects including tumor 
formation. Here, we show that the therapeutic benefit in the 
ECFC-treated mice was still present at 10 months of age with-
out adverse effects on lung structure or exercise capacity. No 
tumors were detectable by examining serial histological sec-
tions of major organs including the lung, brain, heart, liver, 
kidney, and spleen at 10 months post-ECFC injection.
In conclusion, we show for the first time that ECFCs exist in 
the distal vasculature of the developing mammalian lung, and 
their functional capacity is impaired in oxygen-induced lung 
damage. We also show that therapeutic supplementation with 
human umbilical cord blood–derived ECFCs is feasible, effi-
cacious, and apparently safe in this experimental O2-induced 
model of BPD in neonatal mice.
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CLINICAL PERSPECTIVE
Preterm delivery is a major healthcare problem, affecting 10% of all births and accounting for > 85% of all perinatal com-
plications and death. Each year, 5000 to 10 000 newborns experience bronchopulmonary dysplasia, a chronic lung disease 
that follows ventilator and oxygen therapy for acute respiratory failure after premature birth. Bronchopulmonary dysplasia 
is characterized by the interrupted development of alveolar and vascular structures, and currently lacks specific therapeutic 
options. Alarming reports are now emerging suggesting that impaired lung development may manifest at adulthood leading 
to early-onset emphysema and pulmonary hypertension. Evidence suggests that angiogenesis contributes to alveolar growth. 
Here, we demonstrate that developing human and rat lungs harbor resident endothelial colony-forming cells , a subset 
of endothelial progenitor cells, capable of self-renewal and de novo vessel formation in vivo. Hyperoxia, a stimulus that 
contributes to bronchopulmonary dysplasia, perturbs human and rat lung endothelial colony colony-forming cell function 
in vitro and in vivo in experimental oxygen-induced bronchopulmonary dysplasia, respectively. Furthermore, exogenous, 
human cord blood–derived endothelial colony colony-forming cells restore normal lung alveolar and vascular growth and 
function and attenuate pulmonary hypertension. This effect is mediated through a paracrine effect. The improvement in lung 
structure and pulmonary hypertension persisted at 10 months with no adverse effects on lung structure and exercise capacity 
in hyperoxic-exposed animals. Human cord blood–derived endothelial colony colony-forming cells may represent a new 
therapeutic option for lung diseases characterized by impaired alveolar growth. These findings may ultimately extend to 
adult diseases associated with pulmonary hypertension or ischemic diseases.
 by guest on D
ecem
ber 22, 2016
http://circ.ahajournals.org/
D
ow
nloaded from
 
Zhong, Merv Yoder and Bernard Thébaud
Lavinia Ionescu, Megan O'Reilly, Robin K. Ohls, Suzanne McConaghy, Farah Eaton, Shumei 
Rajesh S. Alphonse, Arul Vadivel, Moses Fung, William Chris Shelley, Paul John Critser,
Colony-Forming Cells in Oxygen-Induced Arrested Alveolar Growth
Existence, Functional Impairment, and Lung Repair Potential of Endothelial
Print ISSN: 0009-7322. Online ISSN: 1524-4539 
Copyright © 2014 American Heart Association, Inc. All rights reserved.
is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231Circulation 
doi: 10.1161/CIRCULATIONAHA.114.009124
2014;129:2144-2157; originally published online April 7, 2014;Circulation. 
 http://circ.ahajournals.org/content/129/21/2144
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
 http://circ.ahajournals.org/content/suppl/2014/04/02/CIRCULATIONAHA.114.009124.DC1.html
Data Supplement (unedited) at:
  
 http://circ.ahajournals.org//subscriptions/
is online at: Circulation  Information about subscribing to Subscriptions:
  
 http://www.lww.com/reprints
 Information about reprints can be found online at: Reprints:
  
document. Permissions and Rights Question and Answer this process is available in the
click Request Permissions in the middle column of the Web page under Services. Further information about
Office. Once the online version of the published article for which permission is being requested is located, 
 can be obtained via RightsLink, a service of the Copyright Clearance Center, not the EditorialCirculationin
 Requests for permissions to reproduce figures, tables, or portions of articles originally publishedPermissions:
 by guest on D
ecem
ber 22, 2016
http://circ.ahajournals.org/
D
ow
nloaded from
 
SUPPLEMENTAL MATERIAL 
Existence, Functional Impairment And Lung Repair Potential of Endothelial 
Colony Forming Cells In Oxygen-Induced Arrested Alveolar Growth 
 
First Author: Alphonse 
Short title: Endothelial colony forming cells for lung repair 
Rajesh S Alphonse, MD, PhD1, Arul Vadivel, PhD2, Moses Fung, BSc1, William Chris Shelley, BSc3, 
Paul John Critser, MD, PhD3, Lavinia Ionescu1, PhD, Megan O’Reilly1, PhD, Robin K Ohls4, MD, 
Suzanne McConaghy, MSc4, Farah Eaton, BSc1, Shumei Zhong, MSc2, Merv Yoder, MD3, Bernard 
Thébaud, MD, PhD2 
1 Department of Pediatrics, Women and Children’s Health Research Institute, Cardiovascular Research 
Center and Pulmonary Research Group, University of Alberta, Edmonton, Canada 
2 Ottawa Hospital Research Institute, Regenerative Medicine Program, Sprott Center for Stem Cell 
Research, Department of Pediatrics, Children’s Hospital of Eastern Ontario, University of Ottawa, 
Ottawa, Ontario, Canada 
3 Department of Pediatrics, Herman B Wells Center for Pediatrics Research, Division of Neonatal-
Perinatal Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA 
4 Department of Pediatrics, University of New Mexico, Albuquerque, New Mexico, USA 
 
Correspondence:  
Dr. Bernard Thébaud 
Ottawa Hospital Research Institute 
501 Smyth Road 
Ottawa, ON K1H 8L6, Canada  
Phone: 613-737-8899, Fax: 613 739-6294 
E-mail: bthebaud@ohri 
  
 
Materials and Methods  
 
All procedures were approved by the Animal Health Care Committee of the University of Alberta. 
Human fetal tissue collection was reviewed by the Institutional Review Board at the University of New 
Mexico and was determined to not constitute human subject research, as no identifying information 
was collected with tissues that would otherwise be discarded.  The investigators collecting the tissues 
were not involved in the consent process and had no contact with women consenting to the termination 
procedure. 
 
Lung ECFC isolation and culture 
Human fetal lungs (n=3, 17-20 weeks gestational age) were collected within 60 minutes after 
termination, washed in sterile PBS with antimicrobials, and suspended for further processing in a-
MEM with 10% FCS and antimicrobials. Rat lungs were collected at postnatal day (P)14 (n=5/group). 
Under aseptic conditions, the peripheral rims of the lungs were cut out, chopped into 1-2 mm2 pieces 
and suspended in digestive solution (0.1 U collagenase and 0.8 U dispase/mL) (Roche Applied Science, 
Laval, QC) at 37 oC for 1 hr with intermittent shaking. The lung digest was strained through 70mm and 
40mm cell strainers in tandem and washed twice with DMEM plus 10% fetal calf serum (FCS), at 300g 
and 4 oC for 10 min. After washing, the cells were resuspended in phosphate buffered saline (PBS) 
containing 0.1% (w/v) bovine serum albumin (BSA) and incubated with streptavidin tagged dynabeads 
(Dynal, Invitrogen, Burlington, ON) that were pretreated with biotinylated anti-rat or anti-human CD31 
antibody (Abcam, Cambridge, MA). The dynabead tagged CD31 positive cells were selected using a 
magnetic separator and plated in a 6-well plate (4000-5000 cells/well) precoated with rat tail collagen 
type I and placed in a 37 oC, 5% CO2 humidified incubator. After 24 hrs of culture, non-adherent cells 
and debris were aspirated, adherent cells were washed once and added with complete Endothelial 
Growth Medium-2 (cEGM-2). Medium was changed daily for 7 days and then every other day up to 14 
days. ECFC colonies appeared as a well-circumscribed monolayer of cobblestone-appearing cells, 
between 5 and 14 days. ECFC colonies were identified daily from day 5 and enumerated on day 7 by 
visual inspection using an inverted microscope (Olympus, Lake Success, NY), under 20X 
magnification. Individual ECFC colonies were marked with a fine tipped marker and clonally isolated 
using cloning cylinders (Fisher Scientific, Ottawa, ON) and plated in T25 flasks pretreated with 
collagen type I. Upon confluence, ECFCs were plated and expanded in type I collagen coated T75 
flasks. ECFCs between passages 4-8 were used for all experiments. 
 
DiI-acetylated-low density lipoprotein (DiI-Ac-LDL) uptake and Ulex europaeus-lectin binding 
Attached cells at passage 4-5 were incubated with 20 µg/mL DiI-Ac-LDL (Biomedical technologies, 
Stoughton, MA) in cEGM-2 media for 4 hrs at 37 °C, 5% CO2 in a humidified incubator. Cells were 
washed several times and fixed with 2% paraformaldehyde for 10 min. After washing with PBS, the 
cells were reacted with 10µg/ml fluorescein tagged Ulex europaeus-lectin (Vector Laboratories, 
Burlingame, USA) for 1h. Following nuclear counterstaining with Hoechst 33258, double-stained 
DiIAc-LDL+/FITC-Lectin+ cells were imaged with an inverted fluorescence microscope (Leica 
Microsystems, Richmond Hill, ON, Canada). 
 
Immunophenotyping of ECFCs 
Early passage (4-5) ECFCs (0.25-0.5 million per sample) were washed in flow buffer (PBS containing 
0.05% sodium azide and 0.1% BSA) and blocked by incubation for 1 hr in 100µL of flow buffer 
containing 5% milk. ECFCs were then incubated at 4 oC for 30-60 minutes in dark with appropriate 
concentrations of primary or isotype control antibody, as outlined below, in 50µL of 5% milk-flow 
buffer. After washing, if necessary, the cells were incubated in dark, with comparable concentrations of 
secondary antibody in 50µL of 5% milk-flow buffer. After washing, antibody-labeled ECFCs were 
analyzed by fluorescence-activated cell sorting (FACS) (FACSCalibur, BD Biosciences, San Diego, 
CA)1. 
 
Retroviral mediated eGFP labelling of ECFCs 
By screening multiple Human Immunodeficiency Virus (HIV)-1 based lentiviral vectors for optimal 
transduction efficiency to ECFCs, we selected a vesicular stomatitis virus (VSV)-pseudotyped 
lentiviral vector harboring enhanced Green fluorescence protein (eGFP) under the control of ubiquitous 
Elogation factor (EF)-1 promoter (LV-EF-eGFP). Rat lung ECFCs in passage 4-5 were incubated 
overnight with 2 x 106 TU/ml of lentiviral vector and 7 µg/ml protamine sulfate in cEGM-2. ECFCs in 
wells with uniform green fluorescence were trypsinized, expanded and sorted for GFP fluorescence 
using FACS. 
 
In Vitro Cell Viability Assay 
Lung ECFCs obtained from hyperoxia-exposed and room-air (control) rat pups were plated in equal 
numbers and grown in identical culture conditions. Cell viability was evaluated at various time points 
using the MTT assay as previously described. 
 
Capillary-like network formation in Matrigel 
The formation of cord-like structures by ECFCs was assessed on Matrigel (BD Biosciences, 
Mississauga, ON) coated 96-well tissue culture plates as previously described2. The capillary-like 
networks were quantified by measuring the number of intersects and the total length of cord-like 
structures in random fields from each well using OpenLab (Quorum Technologies Inc, ON, Canada) 
software. 
 
Single cell clonogenicity 
The FACSAria cell sorter (BD Biosciences, Mississauga, ON) was used to place one ECFC per well in 
a flat-bottomed 96-well tissue culture plate precoated with type I collagen and containing 200 µL 
complete EGM-2 media. Cells were cultured at 5% CO2 and 37 °C in a humidified incubator and 
culture media was replaced twice/week. At day 14, Hoechst 33258 (Sigma) was added at 3 µg/mL to 
each well for 10 min for nuclear detection. The culture plate was examined with a fluorescent 
microscope at 20X magnification, well by well, for the growth of endothelial cells. Wells with 2 or 
more endothelial cells were scored as positive. The number of cells per well was enumerated by visual 
inspection at 40X magnification. Colonies with more than 500 cells were trypsinized and resuspended 
in cEGM-2. Based on the number of cells in that colony, an appropriate amount of cEGM-2 was added 
and mixed well such that each 200 µL would approximately contain one ECFC. From this suspension, 
cells were again seeded at single cell density in 96-well plates precoated with collagen type-I, cultured 
for 2 weeks and evaluated for secondary colonies (or second generation colonies), as described earlier. 
ECFCs from colonies with more than 500 cells were serially passaged in 24-well and 6-well tissue 
culture plates followed by T25 and T75 tissue culture flasks. 
 
De novo angiogenesis in vivo 
ECFCs were loaded on collagen-fibronectin matrices and implanted subcutaneously in NOD/SCID 
mice to assess their capacity to contribute to de novo vasculogenesis as described3. ECFCs were 
identified by antibody specific for human CD31 (Dako, Carpenteria, CA) that cross-reacts with rat but 
no mouse endothelial cells. Cellularized collagen-fibronectin implants were excised after 14 days post-
implantation and examined for vascularization by immunohistochemical staining. Red blood cell 
perfused anti-human CD31+ vessels were identified in implants loaded with human or rat ECFCs 
respectively.  
 
Oxygen-Induced BPD Model 
We used two rodent models of oxygen-induced BPD: 1) For comparison of lung ECFC function, 
newborn rat pups were exposed to room air (21%; control group) or hyperoxia (95% oxygen; BPD 
group) from birth to P14 in sealed Plexiglas chambers (OxyCycler; BioSpherix, Lacona, NY) with 
continuous oxygen monitoring and ECFCs were isolated at P14 for comparative analysis2; 2) To test 
the therapeutic potential of human cord blood-derived ECFCs, immune-compromised newborn rag-/- 
mice were exposed to 85% oxygen from P4 to P14. Human cord-derived ECFCs, isolated, expanded, 
and quality controlled as previously described1 were administered at P14 through the jugular vein (105 
cells/mouse in 100 µL DMEM). Lungs were harvested at P28. For cell engraftment experiments, 
ECFCs were labeled prior to injection with a red fluorophore (CellBriteTM Cytoplasmic Membrane 
Staining Kit, Biotium Inc, Hayward, CA). A subset of mice was kept for long-term assessment until 10 
months of age.  
 
Lung Morphometry 
Lungs were fixed with a 4% glutaraldehyde solution through the trachea under a constant pressure of 
20 cm H2O. The trachea was ligated, and the lungs were immersed in fixative overnight at 4°C. Lung 
volume was measured by water displacement4. Lungs were embedded in paraffin and serial step 
sections, 4 mm in thickness, were taken along the longitudinal axis of the lobe. The fixed distance 
between sections was calculated so as to allow a systematic sampling of 10 sections across the whole 
lobe. Lungs were stained with hematoxylin and eosin (H&E). Alveolar structures were quantified on a 
motorized microscope stage (Leica CTRMIC and openlab software, Quorum Technologies; Guelph, 
ON) by using the mean linear intercept (MLI) as previously described2. 
 
Immunohistochemistry. Sections were incubated with a polyclonal rabbit anti-von Willebrand Factor 
(vWF) antibody (Catalog #A0082; Dako) and a biotinylated secondary antibody (Catalog #B2770; Life 
Technologies Inc., Burlington, ON). A streptavidin-HRP conjugate (Catalog #S-911; Life Technologies 
Inc., Burlington, ON) was used to link the DAB Chromogen  (DAB Catalog # D4293; Sigma Aldrich, 
Oakville, ON) for visualization. Lung capillaries (30-100µm) were quantified on a motorized 
microscope stage.  
 
Right Ventricular Hypertrophy 
The right ventricle free wall was separated from the left ventricle and the septal wall. The tissue was 
dried overnight and weighed the following day5.  
 
Echocardiography 
All evaluations of pulmonary artery flow were performed with a (maximal) sweep speed of 200 mm/s. 
Pulsed-wave Doppler of pulmonary outflow was recorded in the parasternal view at the pulmonary 
valve level. The pulmonary acceleration time (PAAT) was measured from the beginning of the 
pulmonary flow to its onset and normalized with heart rate for comparisons as described5. 
 
Lung function testing 
Tests were performed on anesthetized and paralyzed animals using Flexivent (Scireq, Montreal, QC, 
Canada) as described6.  
 
Real-time PCR 
 Total RNA was extracted from pulverized frozen lungs using Qiagen RNeasy kit (Qiagen, 
Mississauga, ON). RNA was quantified using a Nanodrop system (ND-1000 ThermoFisher Scientific, 
Wilmington, DE) and cDNA was prepared from 1ung RNA using random hexamers. PCR was 
performed on an ABI 7900 and using Taqman Universal PCR master mix (Applied Biosystems), 
Human Alu sequence primers and values were determined from a standard curve prepared from pure 
ECFCs to detect human cells. All results are expressed as a ratio of Alu sequences normalized to 
human 18S. Three animals/group were harvested at 2 hours, 3, 7, 14 and 21 days after injection. 
 
ECFC-derived Conditioned Media (CdM) experiments 
Human umbilical cord-blood ECFCs in passages 4-6 were grown in T75 flasks up to 90% confluence in 
cEGM-2. Following removal of the respective culture medium, cells were rinsed 3 times with PBS and 
serum free DMEM was added. After 24 hours, supernatants were collected, concentrated (25x) and 
desalted by centrifugal filtration (Amicon - Millipore, Billerica, MA) as described6. Upon preparation, 
CdM was pooled, frozen at -80oC and thawed right before use. Control cell CdM was obtained from 
HUVECs.  
In vitro, AT2 were isolated from time-dated fetal day 19.5 rat lungs as described using serial 
differential adhesions to plastic and low-speed centrifugations7. For wound healing assays, 106 cells/mL 
AEC2 were seeded into a plastic 24-well cell culture plate. At ~80 hours, the cell monolayer was 
scraped with a p200 pipette tip and media replaced with CdM or DMEM. The surface area of the 
wound was recorded over time using OpenLab (Quorum Technologies Inc, ON, Canada)7.   
In vivo, CdM was administered daily to newborn rats exposed to hyperoxia through intraperitoneal 
injections at the dose of 7 µl/g6 from P4 to P21 and lungs were harvested at P22. 
 
Exercise capacity 
Mice were run according to a predetermined protocol. Exhaustion was defined as the animal running 
exclusively on the lower third of the treadmill coupled with hitting of the shock panel twice within 30 
seconds6. 
 
Statistical Analysis 
Values are expressed as means ± standard error of the mean (SEM). Statistical comparisons were made 
with ANOVA. Post hoc analysis used Fisher’s probable least significant difference test (Statview 5.1; 
Abacus Concepts, Berkeley, CA). A value of P less than 0.05 was considered statistically significant. 
All endpoints were assessed by investigators blinded to the experimental groups. 
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Figure S-1. Human umbilical cord ECFC therapy reverses alveolar and lung vascular growth 
arrest and attenuates RVH in hyperoxia-exposed newborn RNU rats. A. Representative H&E–
stained lung sections at P28 show the characteristic arrested alveolar growth with larger and fewer 
alveolar structures in untreated hyperoxia-exposed (O2) lungs as compared to control rats housed in 
RA. Intra-jugular administration of ECFCs in O2-exposed animals restored alveolar growth as 
compared to untreated O2-exposed animals. Quantitative assessment of alveolar architecture by the 
mean linear intercept confirms the protective effect of ECFCs on alveolar growth compared to 
untreated O2-exposed animals (n=4-6/group, *P<0.01). ECFCs did not alter lung structure in control 
RA rats. B. Effects of ECFC treatment on pulmonary vessel density assessed on lung sections stained 
with von Willebrand Factor (vWF) at P28. Pulmonary vessel density of 30-100µm sized blood vessels 
per 10 high power fields (40X) was significantly decreased in the lungs of O2-exposed rats compared to 
RA. Intra-jugular injection of ECFCs significantly improved pulmonary vessel density compared to 
untreated O2-exposed animals (n=4-6/group, *P<0.05). C. Hyperoxia-exposed rats displayed 
significant RVH compared to RA housed animals as indicated by the increase in right ventricle/left 
ventricle plus septum (RV/LV+S) ratio compared with controls. ECFC therapy significantly reduced 
RVH in hyperoxic exposed rats compared to untreated O2-exposed rats (n=4-6/group, *P<0.05). 
 
Figure S-2. Human umbilical cord ECFC therapy restores resident lung ECFC function in 
hyperoxia-exposed newborn RNU rats.  A. Comparative single cell clonogenic assay. Colony 
forming potential of single plated ECFCs from RNU rat lungs was assessed by measuring the 
percentage of single ECFCs capable of generating colonies after 14 days in culture. Significantly fewer 
ECFCs from the hyperoxia group were capable of generating colonies with 500 or more cells in 
comparison with RA controls (*P<0.05, n=3 trials/group). Treatment with cord blood-derived ECFCs 
significantly restored the colony forming potential of resident lung ECFCs isolated from treated RNU 
lungs exposed to hyperoxia (*P<0.05, n=3 trials/group). Cell therapy did not alter the colony forming 
properties of ECFCs from control RA rat lungs. B. Quantitative assessment of the in vitro capillary-
like network forming ability of lung ECFCs. Lung resident ECFCs from untreated hyperoxic rats 
formed fewer capillary networks compared to lung ECFCs from untreated hyperoxia-exposed rats as 
assessed by the cord length and number of branch points (n=6/group, *P<0.05). Cord blood ECFC 
therapy restored the ability of hyperoxic resident lung ECFCs to form capillary-like networks as 
assessed by improved total cord length and number of intersects compared to lung ECFCs from 
untreated hyperoxia-exposed RNU rats (n=6/group, *P<0.05). 
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